Sandwich enzyme-immunoassay for dipeptidyl aminopeptidase IV in the serum of people with oral cancer

Mogi, Makio; Harada, Minoru; Hiraoka, B. Yukihiro; Fukasawa, Katsuhiko; Komatsu, Masataka; Nagatsu, Toshiharu

doi:10.1016/0003-9969(86)90028-2

Cited by 12 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies described before show alterations in the levels of the serum DPP-IV enzymatic activity. To our knowledge, only one study reported a decrease of protein sCD26 (but to a lesser extent than ours) in oral cancer patients (Mogi et al, 1986), although the authors measured a higher quantity of protein than we by using the commercial kit. In addition, some of our data are not in accordance with published measurements of DPP-IV enzymatic activities in some diseases such as GC (lower levels than in normal subjects) (Hino et al, 1975), or in some patients of the BCC group (Fujita et al, 1977).…”

Section: Discussioncontrasting

confidence: 71%

Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer

et al. 2000

View full text Add to dashboard Cite

CD26 is an ectoenzyme with dipeptidyl peptidase IV activity expressed on a variety of cell types. Although the function of the high concentration of serum-soluble CD26 (sCD26) is unknown, it may be related to the cleavage of biologically active polypeptides. As CD26 or enzymatic activity levels were previously associated with cancer, we examined the potential diagnostic and prognostic value of preoperative sCD26 measurements by ELISA in colorectal carcinoma patients. We found a highly significant difference between sCD26 levels in healthy donors (mean 559.7 ± 125.5 μg l –1 ) and cancer patients (mean 261.7 ± 138.1 μg l –1 ) ( P < 0.001). A cut-off at 410 μg l –1 gave 90% sensitivity with 90% specificity which means that the diagnostic efficiency of sCD26 is higher than that shown by other markers, particularly in patients at early stages. Moreover, sCD26 as a variable is not related with Dukes’ stage classification, age, gender, tumour location or degree of differentiation. With a follow-up of 2 years until recurrence, preliminary data show that sCD26 can be managed as a prognostic variable of early carcinoma patients. In addition, the origin of sCD26 is discussed. © 2000 Cancer Research Campaign

show abstract

Section: Discussioncontrasting

confidence: 71%

Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Oslo, Norway) using rosette formation with AET-treated SRBC. T lymphocyte piasma membranes were prepared by the method of MENTLEIN et al (5), T lymphocytes were disrupted by a cell disruption bomb (Parr Instrument, Moline, IL, USA), centrifuged at lO.OOOxg for 15 min at 4°C and then ultracentrifuged at 105.000Xg for 2h at 4°C, The plasma membranes were collected as a mierosomal fraction, " P values were determined by using the Mann-Whitney U-test, cultured carcinoma cells, and sera of cancer patients (10); 2) the enzyme activity was decreased in carcinoma tissues (II) and cultured carctnoma cells (10) as compared to the normal counterparts; 3) DPP IV enzyme protein was reduced in sera of orai cancer patients as compared to the normal subjects (12), but these facts did not give complete understanding of the reduction of serum enzyme levels.…”

Section: Discussionmentioning

confidence: 99%

Reduced expression of dipeptidyl peptidase (DPP) IV in peripheral blood T lymphocytes of oral cancer patients

Uematsu

Urade

Yarnaoka

et al. 1996

J Oral Pathology Medicine

View full text Add to dashboard Cite

To investigate the mechanism of decrease of serum DPP IV activity in oral cancer patients, we analyzed the expression of DPP IV in peripheral blood T lymphocytes of oral cancer patients and healthy subjects. Consequently, serum DPP IV activity was found to correlate significantly with the number of peripheral blood lymphocytes (PBL), T lymphocytes and CD26 (identified as DPP IV)+ T lymphocytes in healthy subjects, and the number of PBL and CD26+ T lymphocytes in cancer patients. However, the numbers of PBL and T lymphocytes were significantly less in cancer patients than in healthy subjects. Although the number of CD26+ T lymphocytes was somewhat greater in cancer patients than in healthy subjects, serum DPP IV activity was significantly lower in cancer patients. DPP IV activity and amount of CD26 in T lymphocyte plasma membranes were much less in cancer patients than in healthy subjects. These findings suggest that a decrease in the number of T lymphocytes and the small amount of DPP IV in their plasma membrane may contribute to the decrease of serum DPP IV activity in cancer patients.

show abstract

“…The mechanism that brings about the decrease in DPP IV activity in sera of cancer patients is still unknown. At least, three facts have been found; 1) DPP IV inhibitor was not detected in homogenates of carcinoma tissues, cultured carcinoma cells, and sera of cancer patients (17), 2) the enzyme activity was decreased in carcinoma tissues (8) and cultured carcinoma cells (17) as compared to the normal counterparts, 3) DPP IV enzyme protein was reduced in sera of oral cancer patients as compared to those of the normal subjects (18). Since these facts do not give us the complete understanding of reduction of serum enzyme level, further investigation is necessary to be elucidated the precise mechanism.…”

Section: Discussionmentioning

confidence: 99%

Serum dipeptidyl peptidase (DPP) IV activity in hamster buccal pouch carcinogenesis with 9,10‐dimethyl‐1,2‐benzanthracene

Urade

Uematsu

Mima

et al. 1992

J Oral Pathology Medicine

View full text Add to dashboard Cite

Dynamic change of serum DPP IV activity in carcinogenesis of hamster buccal pouch epithelium with DMBA was investigated. The serum enzyme level in hamster (21.5 +/- 3.1 IU/l serum) was decreased gradually from the 8th to the 10th wk when papillomas were induced by DMBA application (18.9 +/- 2.7 IU/l serum). The enzyme level was further decreased in the formation of carcinoma in situ or early invasive carcinoma (13.2 +/- 0.5 IU/l serum), and reached to less than half of the normal level at the time when tumors were diagnosed as squamous cell carcinoma histologically (8.1 +/- 1.3 IU/l serum). This enzyme level was increased by tumor excision and decreased again by tumor recurrence toward death. These findings suggested that the decrease of serum DPP IV activity occurred from the early stage of hamster buccal pouch carcinogenesis as a tumor-burden marker.

show abstract

Sandwich enzyme-immunoassay for dipeptidyl aminopeptidase IV in the serum of people with oral cancer

Cited by 12 publications

References 14 publications

Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer

Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer

Reduced expression of dipeptidyl peptidase (DPP) IV in peripheral blood T lymphocytes of oral cancer patients

Serum dipeptidyl peptidase (DPP) IV activity in hamster buccal pouch carcinogenesis with 9,10‐dimethyl‐1,2‐benzanthracene

Contact Info

Product

Resources

About